Fig. 3
From: Real-world data of CanAssist Breast- first immunohistochemistry and AI-based prognostic test
Use of CAB in different Ki67 subgroups. (a) Pie chart illustrating the percentage of patients in different Ki67 subgroups (subgroupings done as per the IKWG guidelines). (b) Graph showing CAB risk stratification in Low Ki67 (≤ 5%), Intermediate Ki67 (6–29%), and High Ki67 (≥ 30%) subgroups. Chi squared test was used to calculate the P values on MedCalc software.
